These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Selective estrogen modulators in menopause. Gambacciani M Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250 [TBL] [Abstract][Full Text] [Related]
3. Use of SERMs for treatment in postmenopausal women. Pinkerton JV; Thomas S J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794 [TBL] [Abstract][Full Text] [Related]
4. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Gennari L; Merlotti D; Valleggi F; Martini G; Nuti R Drugs Aging; 2007; 24(5):361-79. PubMed ID: 17503894 [TBL] [Abstract][Full Text] [Related]
5. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (+/-progestogen) treatments. Kloosterboer HJ; Ederveen AG J Steroid Biochem Mol Biol; 2002 Dec; 83(1-5):157-65. PubMed ID: 12650712 [TBL] [Abstract][Full Text] [Related]
6. Antiestrogens--tamoxifen, SERMs and beyond. Dhingra K Invest New Drugs; 1999; 17(3):285-311. PubMed ID: 10665480 [TBL] [Abstract][Full Text] [Related]
7. Tamoxifen, raloxifene and the prevention of breast cancer. Bentrem DJ; Craig Jordan V Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504 [TBL] [Abstract][Full Text] [Related]
8. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Komm BS; Lyttle CR Ann N Y Acad Sci; 2001 Dec; 949():317-26. PubMed ID: 11795370 [TBL] [Abstract][Full Text] [Related]
9. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast. Pickar JH; Komm BS Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836 [TBL] [Abstract][Full Text] [Related]
10. SERMs and SERMs with estrogen for postmenopausal osteoporosis. Bolognese MA Rev Endocr Metab Disord; 2010 Dec; 11(4):253-9. PubMed ID: 20446043 [TBL] [Abstract][Full Text] [Related]
11. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Pinkerton JV; Goldstein SR Menopause; 2010; 17(3):642-53. PubMed ID: 20107426 [TBL] [Abstract][Full Text] [Related]
13. [Selective estrogen receptor modulators (SERMs) in the practice]. Nagykálnai T Magy Onkol; 2002; 46(2):165-75. PubMed ID: 12202896 [TBL] [Abstract][Full Text] [Related]
14. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Lewis JS; Jordan VC Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919 [TBL] [Abstract][Full Text] [Related]
15. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies]. Maeda T; Ke HZ; Simmons H; Thompson D Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137 [TBL] [Abstract][Full Text] [Related]
16. Selective estrogen receptor modulators: an update on recent clinical findings. Shelly W; Draper MW; Krishnan V; Wong M; Jaffe RB Obstet Gynecol Surv; 2008 Mar; 63(3):163-81. PubMed ID: 18279543 [TBL] [Abstract][Full Text] [Related]
18. [What can we expect of raloxifene in the treatment of postmenopausal osteoporosis--views of a gynecologist]. Chmel R; Rob L; Strnad P Ceska Gynekol; 2002 Jul; 67(4):187-91. PubMed ID: 12373918 [TBL] [Abstract][Full Text] [Related]